This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): BI-204, anti-oxidized LDL, anti-oxLDL, MLDL1278A
Description: Anti-oxLDL is a novel full length human IgG1 antibody that selectively targets a specific atherogenic epitope on oxidized LDL (oxLDL). Preclinical studies suggest that there is a strong link between oxLDL and the inflammatory processes that leads to unstable plaque formation in vessel walls. Plaque rupture leads to heart attack and stroke.
Deal Structure: In January 2007, BioInvent announced that it entered into a strategic collaboration with Genentech to co-develop and commercialize BioInvent's BI-204 for the potential treatment of multiple cardiovascular conditions. Genentech will make an upfront payment of $15 million to BioInvent and, in addition, BioInvent could receive further milestone payments of up to $175 million as well as royalties on sales in North America.
Under the terms of the agreement, Genentech and BioInvent will be jointly responsible for clinical development. Genentech will be responsible for, and will solely control, any commercialization of the drug in North America, whilst BioInvent will be responsible for, and will solely control, commercialization in the rest of the world. Throughout development Genentech and BioInvent will share the development costs.
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest...See full deal structure in Biomedtracker
Partners: BioInvent International AB Shire Pharmaceuticals Group PLC
Pink Sheet FDA Actions, In Brief
Additional information available to subscribers only: